BRPI0516470A - uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase - Google Patents

uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase

Info

Publication number
BRPI0516470A
BRPI0516470A BRPI0516470-2A BRPI0516470A BRPI0516470A BR PI0516470 A BRPI0516470 A BR PI0516470A BR PI0516470 A BRPI0516470 A BR PI0516470A BR PI0516470 A BRPI0516470 A BR PI0516470A
Authority
BR
Brazil
Prior art keywords
type
psoriasis
prevention
treatment
interferon
Prior art date
Application number
BRPI0516470-2A
Other languages
English (en)
Inventor
Michel Gilliet
Frank O Nestle
Original Assignee
Universitot Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitot Zuerich filed Critical Universitot Zuerich
Publication of BRPI0516470A publication Critical patent/BRPI0516470A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE UM AGENTE DE BLOQUEIO DO INTERFERON TIPO 1, E, MéTODO DE PREVENçãO E TRATAMENTO DA PSORìASE. A descoberta dos precursores das células dendríticas plasmacitóides (PDC) como células efetoras cruciais com alta produção dos interferons (IFNs) tipo 1 no desenvolvimento prematuro da psoríase, levou à presente invenção de acordo com a qual esse bloqueio dos IFNs tipo 1 pode ser usado para a prevenção e terapia da psoríase. A invenção diz respeito ao uso de um agente de bloqueio do interferon tipo 1, tal como um antagonista do IFN tipo 1 (por exemplo, um anticorpo anti-IFN-<244> ou antagonista do receptor do IFN tipo 1, para a preparação de um medicamento para a prevenção e tratamento da psoríase, e a um método de prevenção e tratamento da psoríase com o uso de um agente de bloqueio do interferon tipo 1.
BRPI0516470-2A 2004-10-07 2005-09-30 uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase BRPI0516470A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04405628 2004-10-07
PCT/CH2005/000566 WO2006037247A1 (en) 2004-10-07 2005-09-30 Type i interferon blocking agents for prevention and treatment of psoriasis

Publications (1)

Publication Number Publication Date
BRPI0516470A true BRPI0516470A (pt) 2008-09-09

Family

ID=35593663

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516470-2A BRPI0516470A (pt) 2004-10-07 2005-09-30 uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase

Country Status (15)

Country Link
US (1) US20090155286A1 (pt)
EP (2) EP2286835A1 (pt)
JP (1) JP2008515819A (pt)
KR (1) KR20070083809A (pt)
CN (1) CN101056654A (pt)
AU (1) AU2005291741B2 (pt)
BR (1) BRPI0516470A (pt)
CA (1) CA2582471A1 (pt)
IL (1) IL182087A0 (pt)
MX (1) MX2007003809A (pt)
NO (1) NO20072024L (pt)
NZ (1) NZ554065A (pt)
RU (2) RU2007116988A (pt)
WO (1) WO2006037247A1 (pt)
ZA (1) ZA200702794B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002246955B2 (en) 2001-01-09 2007-03-22 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
RU2431638C2 (ru) 2005-02-10 2011-10-20 Бэйлор Рисерч Инститьют Моноклональные антитела против интерферона-альфа и способы применения
AU2009245792B2 (en) 2008-05-07 2012-11-01 Coimmune, Inc. Humanized antibodies against human interferon-alpha
FR2968561B1 (fr) * 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
EP2623978A1 (en) * 2012-02-03 2013-08-07 Charité - Universitätsmedizin Berlin CD8+ T-cell subsets as markers for prediction of delayed fracture healing
CN103319608B (zh) * 2013-07-01 2014-08-27 江苏众红生物工程创药研究院有限公司 猪IFNɑ1-Fc融合蛋白及其编码基因和表达方法
WO2015095143A1 (en) 2013-12-16 2015-06-25 The University Of North Carolina At Chapel Hill Depletion of plasmacytoid dendritic cells
CN114292331A (zh) * 2013-12-24 2022-04-08 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
JP7308034B2 (ja) 2016-07-01 2023-07-13 リゾルブ セラピューティクス， エルエルシー 最適化二重ヌクレアーゼ融合物および方法
WO2019040674A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc SOLUBLE INTERFERON RECEPTORS AND USES THEREOF
EP3801599A1 (en) * 2018-06-01 2021-04-14 ILC Therapeutics Ltd Compositions and methods relating to the treatment of diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423147A (en) * 1980-04-11 1983-12-27 Secher David S Monoclonal antibody to interferon-α
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
US4824432A (en) * 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
US4605394A (en) * 1982-12-03 1986-08-12 Simon V. Skurkovich Methods for the treatment of pathological conditions by removing interferon from the organism
DE3211263A1 (de) * 1981-03-31 1983-01-27 Otsuka Pharmaceutical Co. Ltd., Tokyo Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung
EP0139676B1 (en) * 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
DE19919149A1 (de) 1999-04-27 2000-11-16 Wieser Raimund J Von Interferon alpha-2 abgeleitete Peptid-Homodimere und Peptid-Heterodimere
EP1783141A1 (en) * 1999-11-15 2007-05-09 Miltenyi Biotec GmbH Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
GB0001710D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
GB0001712D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
AU2002246955B2 (en) * 2001-01-09 2007-03-22 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
NZ540555A (en) * 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
KR101151477B1 (ko) * 2003-12-10 2012-06-22 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
RU2431638C2 (ru) * 2005-02-10 2011-10-20 Бэйлор Рисерч Инститьют Моноклональные антитела против интерферона-альфа и способы применения

Also Published As

Publication number Publication date
NZ554065A (en) 2010-12-24
US20090155286A1 (en) 2009-06-18
NO20072024L (no) 2007-04-26
KR20070083809A (ko) 2007-08-24
AU2005291741B2 (en) 2011-11-24
AU2005291741A1 (en) 2006-04-13
IL182087A0 (en) 2007-07-24
WO2006037247A1 (en) 2006-04-13
RU2007116988A (ru) 2008-11-20
RU2010146161A (ru) 2012-05-20
EP1796722A1 (en) 2007-06-20
ZA200702794B (en) 2008-06-25
CN101056654A (zh) 2007-10-17
JP2008515819A (ja) 2008-05-15
EP2286835A1 (en) 2011-02-23
CA2582471A1 (en) 2006-04-13
MX2007003809A (es) 2007-09-12

Similar Documents

Publication Publication Date Title
White et al. Antimalarial activity of KAF156 in falciparum and vivax malaria
Ravikirti et al. Ivermectin as a potential treatment for mild to moderate COVID-19–a double blind randomized placebo-controlled trial
BRPI0516470A (pt) uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase
Cegolon et al. Hypothesis to explain the severe form of COVID-19 in Northern Italy
DE60220049D1 (de) Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer
PT99108A (pt) Processo de preparacao de uma composicao farmaceutica a base de portadores naoaquosos de perfluorocarbonetos ou silicone fluorado
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BRPI0608840B8 (pt) composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação
Bastyr III et al. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure
Zheng et al. A novel protein drug, novaferon, as the potential antiviral drug for COVID-19
Nowak et al. Effects of combined modality therapy of head and neck carcinoma on shoulder and head mobility
Jamaati et al. Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran
Tzen et al. Melas with point mutations involving tRNALeu (A3243G) and tRNAGlu (A14693g)
Sulkowski et al. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection
Neri et al. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-α-2a and interferon-α-2b
Shemer et al. Clinical comparison and complete cure rates of terbinafine efficacy in affected onychomycotic toenails
Carter Carter-Thomason uterine suspension and positioning by ligament investment, fixation and truncation.
BR0110512A (pt) Preparação para medir a taxa de esvaziamento gástrico
BR0212917A (pt) Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento
McFaline-Figueroa et al. Advancing β-adrenoreceptor agonism for recovery after volumetric muscle loss through regenerative rehabilitation and biomaterial delivery approaches
BR0212928A (pt) Processo para tratamento de infecção viral de hapatite c em pacientes que não responderam a tratamento
Boudreau et al. Comparison of mefloquine, chloroquine plus pyrimethamine-sulfadoxine (Fansidar), and chloroquine as malarial prophylaxis in eastern Thailand
Moriguchi et al. Treatment of SARS with human interferons
Mita et al. Real-world safety and effectiveness of 24-week sofosbuvir and ribavirin treatment in patients infected with rare chronic hepatitis C virus genotypes 3, 4, 5, or 6 in Japan
Mayo-Pampín et al. Acute generalized exanthematous pustulosis due to pseudoephedrine with positive patch test

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.